Pemigatinib is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma that is unresectable, has been previously treated, and harbors fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements as detected by an FDA-approved test.

2. Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Pemigatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) harboring fibroblast growth factor receptor 1 (FGFR1) rearrangements.

The recommended dose of pemigatinib is 13.5 mg, taken orally once daily for 14 consecutive days, followed by a 7-day break from treatment. This constitutes a 21-day cycle. Treatment should be continued until disease progression occurs or unacceptable toxicities develop.